Observation on the clinical effectiveness of deferasirox, deferiprone and desferrioxamine in the treatment of iron load in patients with thalassemia major

Abstract

Objective To explore the clinical effectiveness of deferasirox, deferiprone and desferrioxamine in the treatment of iron overload in patients with thalassemia major. Methods Among the severe thalassemia patients with iron overload being diagnosis, treated and followed up in Guigang City People′s Hospital, fifty cases were tested by MRI T2 and were detected with cardiac and liver iron overload, the patients were selected and randomly divided into the deferoxamine treatment (DFO) group(18 case), deferiprone treatment (DFP) group (22 cases) and deferasirox treatment (DFX) group (10 case), The baseline data of the three groups were statistically analyzed.the serum ferritin (SF) value, the cardiac MRI T2 value and the liver MRI T2 value before and after treatment were measured. Results The patients completed the treatment, after 1 years of treatment, the serum SF value, cardiac and liver MRI T2 values of the patients were improved than those before the treatment (P 0.05); the differences in liver MRI T2 value among the three groups were not statistically significant(F=0.131, P>0.05), There were significant differences in heart iron load MRI T2 values among the three groups ((34.27 ± 6.30) ms vs.(23 ± 2.79) ms vs.(21.8 ± 2.20)ms, F=39.54, P<0.05). Conclusion Deferoxamine, deferiprone and deferasirox can effectively alleviate the iron load in patients with thalassemia major.in terms of cardiac iron overload, the curative effects of deferiprone treatment in patients with thalassemia is superior than desferrioxamine and deferasirox treatment, it is worthy of clinical promotion. Key words: Thalassemia Major; Iron Chelator; Serum Ferritin; MRI T2*Ttechnology